Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
681-700 of 847 trials

Hereditary Angioedema: Deucrictibant Extended-Release Tablet

We are studying a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The trial will evaluate its safety, effectiveness, and impact on quality of life.

Hereditary Angioedema>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Liver Cirrhosis: RTX001 Macrophage Therapy

We are studying a new treatment using RTX001 autologous macrophages for people with decompensated liver cirrhosis. The trial aims to evaluate its safety and effectiveness in improving liver function.

Liver Cirrhosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

Sjögren’s Disease: Sibeprenlimab Treatment Study

We are investigating whether Sibeprenlimab can improve symptoms in people with Sjögren’s Disease compared to a placebo. The study will also look at the safety and tolerability of this new treatment.

Sjögren's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology

Prucalopride for Refractory Gastro-Esophageal Reflux Disease

We are testing a new medication for patients with GERD who still have symptoms despite taking standard treatments. The goal is to see if this drug can improve their reflux symptoms.

Gastro-esophageal Reflux Disease (GERD)≤3 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Non-Small Cell Lung Cancer: Chemotherapy Plus Osimertinib Study

We are evaluating if adding osimertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have progressed after initial osimertinib treatment. This study compares the new treatment approach to chemotherapy with a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Seizures in Developmental and Epileptic Encephalopathies: LP352 Study

We are investigating whether LP352 can help reduce seizures in children and adults with developmental and epileptic encephalopathies. This study compares the medication to a placebo to assess its effectiveness and safety.

Developmental and Epileptic EncephalopathiesConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Nodal T Cell Lymphoma: Duvelisib vs. Gemcitabine or Bendamustine

We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.

Refractory Adult T-cell LymphomaRelapsed/Refractory Nodal T Cell Lymphoma with TFH Phenotype>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Cabozantinib and Lanreotide Study

We are studying the safety and effectiveness of a new combination treatment for patients with gastroenteropancreatic and thoracic neuroendocrine tumors. This trial aims to find out if this combination can improve treatment outcomes compared to current options.

Gastroenteropancreatic and Thoracic Neuroendocrine TumorEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesEndocrinologyOncology

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinology

Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

Gastric Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterologyOncology

Atherosclerotic Cardiovascular Disease: Maridebart Cafraglutide

We are studying whether maridebart cafraglutide can improve heart health in people with atherosclerotic cardiovascular disease who are overweight or obese. This trial compares its effects to a placebo alongside standard care.

Arteriosclerotic Cardiovascular DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine